Short Interest in OmniAb, Inc. (NASDAQ:OABIW) Declines By 42.4%

OmniAb, Inc. (NASDAQ:OABIW) saw a large drop in short interest in August. As of August 31st, there was short interest totaling 10,640 shares, a drop of 42.4% from the August 15th total of 18,488 shares. Based on an average daily volume of 46,171 shares, the short-interest ratio is currently 0.2 days.

OmniAb Stock Down 40.7%

Shares of OmniAb stock traded down $0.15 during trading on Wednesday, hitting $0.22. 1,790 shares of the stock traded hands, compared to its average volume of 17,180. The company has a fifty day moving average price of $0.16 and a two-hundred day moving average price of $0.12. OmniAb has a twelve month low of $0.04 and a twelve month high of $0.42.

OmniAb Company Profile

OmniAb, Inc is a clinical‐stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high‐throughput screening and bioinformatics, OmniAb aims to streamline the development of next‐generation biologics across a range of disease areas.

At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single‐cell screening capabilities.